Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EquasensFRA:PHF 91 Earnings Yield (Joel Greenblatt) % is 7.94% as of Dec. 2025, which is 58% above its 10-year median of 5.02. GuruFocus rates FRA:PHF with a GF Score™ of 91/100 and a GF Value™ of €87.36. The stock has 3 warning signs investors should review. Among 684 Healthcare Providers & Services companies, Equasens ranks better than 84.5% on this metric.
Equasens's Enterprise Value for the quarter that ended in Dec. 2025 was €777.8 Mil.
Equasens's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €52.4 Mil. Equasens's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 7.94%.
The historical rank and industry rank for Equasens's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:PHF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.61 Med: 5.02 Max: 10.89
Current: 10.5
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Equasens was 10.89%. The lowest was 2.61%. And the median was 5.02%.
FRA:PHF's Earnings Yield (Joel Greenblatt) % is ranked better than 84.5% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 3.71
vs FRA:PHF: 10.50
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Equasens's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 9.38%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Equasens Earnings Yield (Joel Greenblatt) % Related Terms
Equasens Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Equasens's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Equasens's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Equasens's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Equasenss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 7.94% mean?
Equasens (FRA:PHF) has a Earnings Yield (Joel Greenblatt) % of 7.94% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Equasens and its competitors. This is 58% above median its historical median of 5.02. Over the past decade, Equasens' Earnings Yield (Joel Greenblatt) % has ranged from 2.61 to 10.89. According to the industry distribution chart, Equasens ranks #106 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 15.5%.
Is Equasens' Earnings Yield (Joel Greenblatt) % too high?
Equasens' current Earnings Yield (Joel Greenblatt) % of 7.94% is 58% above median its 10-year median of 5.02. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 10.89. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.71. Equasens' value of 7.94% is 114% above this industry median. Based on the distribution chart, Equasens ranks #106 out of 684 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' Earnings Yield (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #106 out of 684 companies for Earnings Yield (Joel Greenblatt) %. This places Equasens in the top 16% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.71. Equasens' value of 7.94% is 114% above this benchmark. Historically, Equasens' own Earnings Yield (Joel Greenblatt) % has ranged from 2.61 to 10.89 over the past decade. While the company's 10-year median is 5.02 vs. the industry median of 3.71, Equasens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.71, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current Earnings Yield (Joel Greenblatt) % of 7.94% is 114% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current Earnings Yield (Joel Greenblatt) % is 7.94%, which is 58% above median its own 10-year median of 5.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current Earnings Yield (Joel Greenblatt) % of 7.94%. The stock's GF Value™ is €87.36, compared to a current price of €52.77 — trading 39.6% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 7.94%, which is 58% above median its 10-year median of 5.02 and 114% above the Healthcare Providers & Services industry median of 3.71. Equasens' overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Equasens (FRA:PHF), the current Earnings Yield (Joel Greenblatt) % is 7.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (FRA:PHF) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €52.77 is trading 39.6% below its estimated GF Value™ of €87.36.
Key valuation signals for FRA:PHF:
Earnings Yield (Joel Greenblatt) %: 7.94% (58% above median its 10-year median of 5.02)
GF Value™: €87.36 vs. price of €52.77 (39.6% below fair value)
Industry Position: 114% above the Healthcare Providers & Services median (#106 of 684)
No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
91GF Score
Get the complete analysis for FRA:PHF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHF has been successfully added to your 
